Rotigotine protects dopaminergic neurons by targeting serotonin 1A receptors on astrocytes
Objective: In this study, we examined neuroprotective effects of rotigotine and involvement of serotonin 1A (5-HT1A) receptors on astrocytes in neuroprotective action of the drug…Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture
Objective: To evaluate the effect of Mate leaves extracts on the survival and maturation of dopaminergic neurons in vitro. Background: Parkinson's disease (PD) is caused…Neuromodulatory role of subthalamic nucleus deep brain stimulation in Parkinson’s disease patients
Objective: The aim of study was to evaluate the impact of subthalamic nucleus deep brain stimulation (STN-DBS) on the motor disabilities and cognitive alterations in…Oral treatment with sphingosine-1-phosphate receptors modulator prevents Parkinson symptoms concomitantly to reduced brain inflammation in MPTP mouse models
Objective: Here we explore the efficacy of an oral treatment with Fingolimod (FTY720), a selective sphingosine-1-phosphate receptors modulator, to prevent MPTP induced nigrostriatal loss and…The NIC-PD-study –A randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson‘s disease in Germany and N. America
Objective: To evaluate the disease modifying potential of transdermal (TD) nicotine in early Parkinson’s disease (PD). For this explanatory purpose, the primary endpoint was the…What makes a successful Phase 2 study: An evaluation of Parkinson’s neuroprotective trial design over the last 5 years
Objective: To evaluate variation in Phase 2 and 3 Parkinson’s disease (PD) neuroprotective trial designs and identify key trial design features in Phase 2 studies…A first-in-human clinical study to test the safety and preliminary efficacy of CDNF in Parkinson’s disease
Objective: To develop a novel disease-modifying therapy in Parkinson's disease (PD) that affects both motor and non-motor symptoms, based on a novel stress-protective protein CDNF.…The Akt/mTOR/P70S6K/4EB-P1 signaling pathway is activated by metformin in a toxin-induced cellular model of Parkinson’s disease
Objective: To investigate the effects of metformin on the Akt/mTOR/P70S6K/4EB-P1 signaling pathway in a cellular model of Parkinson’s disease (PD). Background: Metformin is a drug…Deep Brain Stimulation for Parkinson Disease before L-dopa treatment: experience in three cases.
Objective: The goal of these case series is to investigate the possibility of deep brain stimulation (DBS) prior to L-dopa treatment in young Parkinsson…Predict Cognitive Decline with Clinical Markers in Parkinson’s Disease
Objective: We investigated which clinical-ready and cost-effective markers are predictive of cognitive impairment (CI) in Parkinson’s disease (PD) in a cohort of 294 patients with…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 15
- Next Page »